Enliven Therapeutics prices public offering of 8.9M shares and pre-funded warrants

Enliven Therapeutics is conducting a public offering of 8,933,334 common shares and pre-funded warrants to purchase 1,733,333 shares, with a 1.6M share overallotment option led by Jefferies, Goldman Sachs, Morgan Stanley, and Barclays. The offering provides capital for the clinical-stage biopharmaceutical company to fund operations and development programs.